Table 1 Updates on glofitamab therapy for B cell lymphoma patients
Author | Study type | Regimen | Patients | ORR | CR | Survival |
|---|---|---|---|---|---|---|
Max S. Topp | Phase Ib | Glofitamab combined with R-CHOP | Newly diagnosed untreated DLBCL, N = 56 | 93.5% | 76.1% | – |
Martin Hutchings | Phase I | RO7227166 combined with glofitamab | R/R B-cell lymphoma, N = 71 (46 DLBCL, 24 FL, 1 MZL) | DLBCL:67% FL:91% | DLBCL:39% FL:73% | – |
Anna Dodero | Retrospective | Glofitamab | R/R large B-cell lymphomas, N = 18 | 68% | 38% | 1-year OS: 44% |
Martin Hutchings | Retrospective | Glofitamab | R/R large B-cell lymphoma, N = 61 (41 DLBCL, 18 tFL, 1 HGBCL, 1 PMBCL) | 84% | 56% | – |
Burhan Ferhanoglu | Retrospective (compassionate use) | Glofitamab | R/R large B-cell lymphoma, N = 42 (2 tFL, 40 DLBCL), | 28.5% | 19% | Median OS: 7 months |